Related Experiment Videos
Predicting haloperidol treatment response in chronic schizophrenia
D P van Kammen1, M E Kelley, J K Yao
1Department of Veterans Affairs Medical Center, Pittsburgh, PA 15206-1297, USA. dpvk@pitts-hghlnd.va.gov
Psychiatry Research
|August 30, 1996
Summary
Predicting schizophrenia treatment response is complex. Later age of onset and dopamine activity (homovanillic acid) predict remission, while noradrenergic activity (3-methoxy-4-hydroxyphenylglycol) and neurodevelopment predict symptom improvement with haloperidol.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia treatment response varies significantly among patients.
- Identifying predictive biomarkers for haloperidol treatment is crucial for personalized medicine.
Purpose of the Study:
- To identify pretreatment characteristics predicting remission and clinical improvement in schizophrenic patients treated with haloperidol.
- To explore the roles of dopaminergic and noradrenergic activity in treatment outcomes.
Main Methods:
- A 6-week, double-blind treatment protocol involving 35 acutely relapsed schizophrenic patients.
- Assessment of pretreatment measures for predicting remission status and changes in psychopathology.
- Analysis of plasma homovanillic acid and cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol levels.
Main Results:
- Later age of onset and higher plasma homovanillic acid predicted remission.
- Higher cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol and normal neurodevelopment indices predicted greater psychopathology reduction.
- Dopaminergic activity correlated with remission, while noradrenergic activity correlated with symptom reduction.
Conclusions:
- The definition of drug response influences predictive variables in schizophrenia treatment.
- Both catecholamine activity and neurodevelopmental factors impact haloperidol response.
- Distinct biological pathways may underlie remission versus symptom improvement in schizophrenia.